An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT-Reference-Cited by-同舟云学术

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Published:2023-05-09 Issue:8 Volume:58 Page:916-923
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Beksac Meral^ORCID,Iacobelli Simona,Koster Linda,Cornelissen Jan,Griskevicius Laimonas,Rabin Neil K.,Stoppa Anne Marie,Meijer Ellen,Mear Jean-Baptiste,Zeerleder Sacha,Mayer Jiri,Fenk Roland,Fegueux Nathalie,Chevallier Patrice^ORCID,Konirova Eva,Snowden John A.^ORCID,Engelhardt Monika^ORCID,Orchard Kim,Hulin Cyrille,Schaap Nicolaas,Sossa Claudia,Elmaagacli Ahmet,McLornan Donal P.^ORCID,Hayden Patrick J.^ORCID,Schönland Stefan^ORCID,Yakoub-Agha Ibrahim^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01999-1.pdf

Reference21 articles.

1. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

2. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–68.

3. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37:589–97.

4. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309–22.

5. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma. Transpl Cell Ther. 2022;28:284–93.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma;Journal of Clinical Oncology;2024-05-10

2. High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy;American Journal of Hematology;2024-04-13

3. A rational approach to functional high-risk myeloma;Hematology;2023-12-08

4. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling;Frontiers in Oncology;2023-10-02